Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation
about
sameAs
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesAntibodies as therapeutic agents: vive la renaissance!Antiplatelet and anti-proliferative action of disintegrin from Echis multisquamatis snake venom.Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectivesGlycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease.Tirofiban in acute coronary syndromes.Percutaneous coronary intervention for revascularization of the diabetic patient.Anesthesia for endovascular neurosurgery.Clinical pharmacology of antithrombotic drugs in coronary artery disease.PAR-1 antagonists: current state of evidence.Pharmacology of antiplatelet agents.The pharmacodynamics of antiplatelet compounds in thrombosis treatment.Antiplatelet therapy: current strategies and future trends.A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys.Bilateral subconjunctival hemorrhage secondary to abciximab use: case report.Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.
P2860
Q28199725-94F35166-4F3B-40AE-9DA5-296BC8FCD947Q33193524-3AC18E0C-EF18-4802-A052-043421A8C403Q33619942-F8CFAA7C-A555-42BC-82B2-7F5085C16F4DQ33952693-1CC12E34-58D9-4A26-B3CA-0044231A9B03Q36053248-366A2AFB-262C-41DF-8A55-4B9F545DF76BQ36107187-CBED847C-3DFC-48DC-879D-B1F71FB2114FQ36490365-58942FA1-E5D9-4D49-AE1F-5304F8DD9C12Q36629801-71DF9C9E-2D2A-4E5F-B914-18DA116935E8Q37591007-FDC2A060-9573-4776-BEF2-68D362F1CEF6Q38014344-82DE03E8-BA2A-4137-AF04-53566CDC6748Q38154211-6C36A9FE-7B95-4430-B49A-BC8408DF8A64Q38800853-C0C4232D-C584-4BBF-A874-326766B0FFF4Q40329892-E4904D28-6B96-4BA2-929C-75354C23E879Q42011685-2FFB3D37-89B3-44CF-B5D8-EE9038A43879Q46624805-E706E8B4-3CCE-4E65-B9E0-032EDDD349A7Q50135555-60337372-AF40-49A5-82A3-5624886499DDQ53536244-05D7351F-91F5-44A0-8964-E534811113E6
P2860
Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Abciximab: an updated review o ...... ous coronary revascularisation
@ast
Abciximab: an updated review o ...... ous coronary revascularisation
@en
Abciximab: an updated review o ...... ous coronary revascularisation
@nl
type
label
Abciximab: an updated review o ...... ous coronary revascularisation
@ast
Abciximab: an updated review o ...... ous coronary revascularisation
@en
Abciximab: an updated review o ...... ous coronary revascularisation
@nl
prefLabel
Abciximab: an updated review o ...... ous coronary revascularisation
@ast
Abciximab: an updated review o ...... ous coronary revascularisation
@en
Abciximab: an updated review o ...... ous coronary revascularisation
@nl
P2860
P1433
P1476
Abciximab: an updated review o ...... ous coronary revascularisation
@en
P2093
Jane K McGavin
Karen L Goa
P2860
P304
P356
10.2165/00003495-200363110-00014
P407
P50
P577
2003-01-01T00:00:00Z
P6179
1009305869